Bayesian Capital Management, LP Ascendis Pharma A/S Transaction History

Bayesian Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $970,133 - $1.23 Million	8,013 New	8,013 $1.09 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $209,395 - $309,739	2,432 Added 77.72%	5,561 $700,000
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $270,658 - $325,322	3,129 New	3,129 $292,000
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $59,652 - $79,182	600 Added 10.17%	6,500 $793,000
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $285,702 - $374,782	3,400 Added 136.0%	5,900 $609,000
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $244,780 - $368,707	-3,135 Reduced 55.63%	2,500 $232,000
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $575,784 - $764,951	5,635 New	5,635 $661,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.